CNM-Au8
Small Molecule Target: NAD+, mitochondrial dysfunction
Clene Inc.
Most recent annual filing: 2026-03-15
Pipeline (5 active programs)
Technology platforms
CSN
Clean-surfaced nanotechnology (CSN) electro-crystal-chemistry platform producing catalytically-active, faceted nanocrystals and ionic solutions from transition elements. Enables development of nanotherapeutics targeting cellular energy impairments in neurodegenerative and other diseases. Flexible and tunable — can produce gold, gold-platinum, and other elemental or composite nanocrystals, plus ionic solutions of silver, zinc, and other transition elements.
Targets: NAD+, mitochondrial dysfunction, reactive oxygen species
electro-crystal-chemistry
Electro-crystal-chemistry drug development platform enabling production of concentrated, stable, highly active, clean-surfaced nanocrystal suspensions; focus on central nervous system disorders including ALS, MS, and Parkinson's disease
Biotech Distilled coverage (9)
- 2026-05-15 UPDATE: Clene Inc. (CLNN) – The Q1 10-Q Answers Three Questions I Left Open 🔒 Paid
- 2026-05-05 UPDATE: Clene Inc. (CLNN) - The Raise-Into-Strength Trade, Same Day 🔒 Paid
- 2026-05-04 UPDATE: Clene Inc. (CLNN) – The Tofersen Precedent Just Landed
- 2026-03-21 UPDATE: Clene Inc. (CLNN) – The Hidden Catalyst of Non-Dilutive Funding 🔒 Paid
- 2026-03-14 UPDATE: Clene Inc. (CLNN) – 2025 Earnings Confirm the Dilution Thesis and the Timeline 🔒 Paid
- 2026-02-28 UPDATE: Clene Inc. (CLNN) – The FDA Showdown Officially Gets a Timeline 🔒 Paid
- 2026-01-13 UPDATE: Clene Inc. (CLNN) – A Sell the News Moment & The Science Behind It 🔒 Paid
- 2026-01-12 UPDATE: Clene Inc. (CLNN) – The Dilution Gap Is Effectively Gone for 12-Months. Now It’s Just Science 🔒 Paid
- 2025-12-30 Clene Inc (CLNN): Scientific Due Diligence for CNM-Au8 and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.